Drugs /

platinum doublet therapy

Back to Drugs List
Associated Diseases

Overview

NCI Definition [1]:
A drug combination of a platinum agent, such as cisplatin (CDDP), carboplatin (CBDCA) or nedaplatin (CDGP), and a third-generation agent, such as docetaxel (DTX), paclitaxel (PTX), vinorelbine (VNR), gemcitabine (GEM), irinotecan (CPT-11), pemetrexed (PEM), or tegafur/gimeracil/oteracil (S-1).

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for platinum doublet therapy

Platinum doublet therapy has been investigated in 7 clinical trials, of which 6 are open and 1 is closed. Of the trials investigating platinum doublet therapy, 4 are phase 2 (3 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for platinum doublet therapy clinical trials.

Non-small cell lung carcinoma is the most common disease being investigated in platinum doublet therapy clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Platinum Doublet Therapy
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Platinum Doublet Therapy
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating platinum doublet therapy and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
platinum doublet, platinum doublets, platinum-based chemotherapy doublet, platinum-based chemotherapy doublets, platinum-based double chemotherapy combination, platinum-based doublet, platinum-based doublets
NCIT ID [1]:
C162261

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.